Journal of General Internal Medicine

, Volume 25, Issue 11, pp 1157–1163 | Cite as

Proximal Tumors Are Associated with Greater Mortality in Colon Cancer

Original Research



Colon cancer is the third leading cause of death from cancer in the United States. Recent studies report on increasing proportions of proximal cancers. The etiology behind this epidemiological trend is unclear, and its implication on survival outcomes is unknown. Further analysis of the impact of anatomic site of disease among a large multiethnic population will help facilitate research and education to improve colon cancer screening and treatment.


To investigate the association between proximal tumor location and survival in patients with colon cancer.


A large retrospective cohort study in the US utilizing the Surveillance, Epidemiology, and End Results (SEER) cancer registry analyzed survival outcomes of patients with colon cancer. Multivariable logistic regression analyses investigated sex-specific, race/ethnicity-specific, and anatomic site-specific disparities in survival.


Five-year survival outcomes from colon cancer.


Our study demonstrated significant disparities in survival by sex, race/ethnicity, and anatomic site. Across all time periods and among most cohorts, patients with proximal cancers had significantly worse survival outcomes. When compared to distal cancers, patients with proximal cancers were 13% less likely to survive 5 years (OR 0.87; 95% CI, 0.82–0.91). When compared to non-Hispanic whites, blacks were 30% less likely to survive 5 years (OR 0.70; 95% CI, 0.68–0.73). Stage-specific multivariable regression analysis of localized cancers demonstrated similar findings.


Significant race-specific, sex-specific, and anatomic site-specific disparities in colon cancer survival exist. Proximal cancers are associated with worse survival odds. These disparities may reflect differences in the genotype and phenotype of colon cancer among these groups. A modified risk assessment tool that incorporates these variations may be more effective in the early detection and treatment of colon cancer.


colorectal cancer cancer screening epidemiology 


  1. 1.
    American Cancer Society. Cancer Facts and Figures 2009. Atlanta: American Cancer Soc; 2009. Accessed at on July 3, 2010.
  2. 2.
    Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. American Cancer Society Colorectal Cancer Advisory Group. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.CrossRefPubMedGoogle Scholar
  3. 3.
    Cooper GS, Yuan Z, Landefeld S, et al. A national population based study of incidence of colorectal cancer and age. Cancer. 1995;75:775–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. New Engl J Med. 1993;329:1977–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Singh SM, Paszat LF, Li C, He J, Vinden C, Rabeneck L. Association of socioeconomic status and receipt of colorectal cancer investigations: a population-based retrospective cohort study. CMAJ. 2004;171:461–5.PubMedGoogle Scholar
  6. 6.
    Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Agrawal S, Bhupinderjit A, Bhutani M, et al. Colorectal cancer in African Americans. Am J Gastroenterol. 2005;100:515–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Chu KC, Miller B, Springfield S. Measures of racial/ethnic health disparities in cancer mortality rates and the influence of socioeconomic status. J Natl Med Assoc. 2007;99:1092–1104.PubMedGoogle Scholar
  9. 9.
    Irby K, Anderson W, Henson D, et al. Emerging and widening colorectal carcinoma disparities between blacks and whites in the United States (1975–2002). Cancer Epidemiol Biomarkers Prev. 2006;15:792–97.CrossRefPubMedGoogle Scholar
  10. 10.
    Carethers JM. Race and ethnic factors in the genetic pathogenesis of colorectal cancer. J Assoc Acad Minor Phys. 1999;10:59–67.PubMedGoogle Scholar
  11. 11.
    Wong RJ. Marked variations in colon cancer epidemiology: sex-specific and race/ethnicity-specific disparities. Gastroenterol Res. 2009;5:268–76.Google Scholar
  12. 12.
    Rabeneck L, Davila JA, El-Serag HB. Is there a true “shift” to the right colon in the incidence of colorectal cancer? Am J Gastroenterol. 2003;98:1400–09.PubMedGoogle Scholar
  13. 13.
    Cucino C, Buchner AM, Sonnenberg A. Continued rightward shift of colorectal cancer. Dis Colon Rectum. 2002;45:1035–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Rabeneck L, Lewis JD, Paszat LF, Saskin R, Stukel TA. Risk of proximal and distal colorectal cancer following flexible sigmoidoscopy: a population-based cohort study. Am J Gastroenterol. 2008;108:2075–82.CrossRefGoogle Scholar
  15. 15.
    Lakoff J, Paszat LF, Saskin R, Rabeneck L. Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. Clin Gastroenterol Hepatol. 2008;6:1117–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8.PubMedGoogle Scholar
  17. 17.
    Bressler B, Paszat LF, Vinden C, Li C, He J, Rabeneck L. Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology. 2004;127:452–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Ransohoff DF. Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med. 2008;359:1218–24.CrossRefPubMedGoogle Scholar
  19. 19.
    Ries LAG, Melbert D, Krapcho M, et al., eds. SEER cancer statistics review, 1975–2005. Bethesda, MD: National Cancer Institute; 2008.Google Scholar
  20. 20.
    Surveillance, Epidemiology, and End Results (SEER) Program Public Use CD-ROM. (1973-2005). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008.Google Scholar
  21. 21.
    World Health Organization. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.Google Scholar
  22. 22.
    Young JL, Roffers SD, Ries LAG, et al., eds. SEER Summary Staging Manual–2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001.Google Scholar
  23. 23.
    Silva IS. Cancer Epidemiology: Principles and Methods. Geneva, Switzerland: World Health Organization; 2001.Google Scholar
  24. 24.
    Gervaz P, Bucher P, Morel P. Two colons—two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88:261–266.CrossRefPubMedGoogle Scholar
  25. 25.
    Chirieac LR, Shen L, Catalano PJ, et al. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am J Surg Pathol. 2005;29:429–436.CrossRefPubMedGoogle Scholar
  26. 26.
    Konishi K, Fujii T, Boku N, et al. Clinicopathological differences between colonic and rectal carcinomas: are they based on the same mechanism of carcinogenesis? Gut. 1999;45:818–821.CrossRefPubMedGoogle Scholar
  27. 27.
    Hurlstone DP, Cross SS, Adam I, et al. A prospective clinicopathological and endoscopic evaluation of flat and depressed colorectal lesions in the United Kingdom. Am J Gastroenterol. 2003;98:2543–2549.CrossRefPubMedGoogle Scholar
  28. 28.
    Ross AS, Waxman I. Flat and depressed neoplasms of the colon in western populations. Am J Gastroenterol. 2006;101:172–180.CrossRefPubMedGoogle Scholar
  29. 29.
    Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterol. 2010;138:2073–2087.CrossRefGoogle Scholar
  30. 30.
    Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labranci R, Hamilton SR. Defective mismatch repair as a predictive marker for lack of efficacy of Fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 [E-pub ahead of print] PMID:20498393.Google Scholar
  31. 31.
    Mchutchinson L, Poynard T, Pianko S, et al. The impact of interferon plus ribivirin on response to therapy in blacks with chronic hepatitis C. Gastroenterology. 2000;119:1317–23.CrossRefGoogle Scholar
  32. 32.
    Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med. 2007;5:444–52.CrossRefPubMedGoogle Scholar
  33. 33.
    The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;228:2891–97.Google Scholar
  34. 34.
    Gibbs CR, Beevers DG, Lip GY. The management of hypertensive disease in black patients. Q J Med. 1999;92:187–92.Google Scholar
  35. 35.
    Wong RJ, Corley DA. Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci. 2009;54:2031–2039.CrossRefPubMedGoogle Scholar
  36. 36.
    Wong RJ. Marked Variations in Proximal Colon Cancer Survival by Race/Ethnicity Within the United States. J Clin Gastroenterol. 2009 [Epub ahead of print] PMID: 19996985Google Scholar

Copyright information

© Society of General Internal Medicine 2010

Authors and Affiliations

  1. 1.Department of MedicineCalifornia Pacific Medical CenterSan FranciscoUSA

Personalised recommendations